EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Orofacial adverse events associated with glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study

Stella O Oyewole, Adepitan A Owosho

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · 2026-10 · 142 (4) · 609-615

DOI: 10.1016/j.oooo.2026.06.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2026-10. Verfasst von Stella O Oyewole und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Cincinnati, Cincinnati, OH, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Mouth Diseases, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study quantifies orofacial adverse event risks associated with Glucagon‑like peptide‑1 receptor agonists (GLP-1RAs), addressing public concerns like "Ozempic teeth/mouth/tongue" Using a large-scale matched cohort, it clarifies associations between GLP-1RA therapy and oral health. MATERIALS AND METHODS: We performed a retrospective cohort analysis within the TriNetX research network, comparing GLP‑1RA users with age‑ and sex‑matched controls in a 1:1 propensity‑matched design. Individuals with prior orofacial conditions or predisposing therapies to adverse outcomes were excluded. ICD-10 codes identified orofacial adverse outcomes across mucosal, salivary, neuropathic, and dental categories. Odds ratio (OR) and 95% confidence intervals were calculated to assess orofacial adverse event risks. RESULT: A cohort of 226,485 GLP‑1RA users was analyzed after exclusions and matching. Gastroesophageal reflux disease (GERD) (5.36%) was the most frequent event, while most conditions were rare. Compared with controls, GLP‑1RA therapy did not increase risk for most outcomes and showed significant inverse associations for multiple mucosal, neuropathic, salivary, and dental conditions (OR = 0.893-0.295). Only GERD (OR = 1.329 [1.291-1.367]) demonstrated significant increased odds. CONCLUSION: The findings of this observational data suggest that GLP-1RAs do not increase the risk of most orofacial conditions and may be inversely associated with mucosal, neuropathic, salivary, and dental disorders. However, clinicians should monitor for GERD-related symptoms. Further prospective research is required to validate these associations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsMouth DiseasesHypoglycemic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedRisk FactorsAdult

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA; Oral Medicine, Dental Oncology and Urgent Care Unit, Missouri S…

Zitieren

APA

Oyewole, S. O., & Owosho, A. A. (2026). Orofacial adverse events associated with glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 142(4), 609-615. https://doi.org/10.1016/j.oooo.2026.06.002

Vancouver

Oyewole SO, Owosho AA. Orofacial adverse events associated with glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2026;142(4):609-615. doi:10.1016/j.oooo.2026.06.002

BibTeX
@article{Oyewole2026,
  author = {Oyewole, Stella O and Owosho, Adepitan A},
  title = {Orofacial adverse events associated with glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study},
  journal = {Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology},
  year = {2026},
  volume = {142},
  number = {4},
  pages = {609--615},
  doi = {10.1016/j.oooo.2026.06.002}
}
Kostenlos starten →